Evgen Pharma (GB:TCF) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TheraCryf plc, a UK-based clinical stage drug development company specializing in oncology and neuropsychiatry, has issued over 2.27 million new ordinary shares to cover professional fees. This move brings the company’s total shares in issue to 429.6 million, offering potential investors an opportunity to engage with its promising pipeline of treatments. TheraCryf is listed on AIM in London under the ticker TCF.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.